COVID-19 Pulmonary Failure and Extracorporeal Membrane Oxygenation: First Experience from Three European Extracorporeal Membrane Oxygenation Centers
Autor: | Patrick Meybohm, Stephane Ledot, Christopher Lotz, Richard Trimlett, José L. Pomar, Charles A. Yankah, Susanna Price, Elena Sandoval |
---|---|
Rok vydání: | 2020 |
Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Time Factors Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Clinical Decision-Making Hospital mortality 030204 cardiovascular system & hematology Risk Assessment 03 medical and health sciences 0302 clinical medicine Extracorporeal Membrane Oxygenation Risk Factors Intensive care Extracorporeal membrane oxygenation Medicine Humans Acute respiratory failure 030212 general & internal medicine Hospital Mortality Aged Mechanical ventilation business.industry COVID-19 Mean age Recovery of Function Middle Aged Europe surgical procedures operative Treatment Outcome Emergency medicine Videoconferencing Surgery Female Pulmonary failure business Cardiology and Cardiovascular Medicine |
Zdroj: | The Thoracic and Cardiovascular Surgeon |
ISSN: | 1439-1902 |
Popis: | On April 17, 2020, a coronavirus disease 2019 (COVID-19) webinar was held by selected international experts in the field of intensive care and specialized respiratory ECMO centers from Germany, Italy, Spain, and the United Kingdom, which was hosted by the German Heart Centre Berlin/Charité. The experts shared their experience about the treatment of 42 patients with severe acute respiratory failure requiring venovenous extracorporeal membrane oxygenation (VV-ECMO). Patients were predominantly male (male-to-female ratio: 3:1), with a mean age of 51 years (range: 25–73 years). VV-ECMO support was indicated in 30% of the ventilated COVID-19 patients. The mean time requiring mechanical ventilation was 16.5 days, with a mean duration of ECMO support of 10.6 days. At the time of the webinar, a total of 17 patients had already been decannulated from ECMO, whereas six died with multiorgan failure. 18 patients remained on ECMO, with their final outcomes unknown at the time of the webinar. Hospital mortality was 25.6% (as of April 17, 2020). In this respect, VV-ECMO, provided by expert centers, is a recognized and validated mode of advanced life-support during the recent COVID-19 pandemic with good outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |